Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients

Yonah B. Esterson, Kehao Zhang, Sudha Koppaka, Sylvia Kehlenbrink, Preeti Kishore, Pooja Raghavan, Sylvan Roger Maginley, Michelle Carey, Meredith A. Hawkins

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using indepth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. Materials and Methods: Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, doubleblind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo. Results: Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1). Conclusions: These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.

Original languageEnglish (US)
Pages (from-to)1152-1160
Number of pages9
JournalJournal of Investigative Medicine
Volume61
Issue number8
DOIs
StatePublished - Dec 2013

Fingerprint

pioglitazone
Thiazolidinediones
Medical problems
Type 2 Diabetes Mellitus
Anti-Inflammatory Agents
Insulin
Placebos
Tissue
Insulin Resistance
Adipose Tissue
Fats
Glucose
Biopsy
Macrophages
Subcutaneous Fat
Physiology
Clamping devices
Nitric Oxide Synthase Type II
Infiltration
Cross-Over Studies

Keywords

  • Adipose tissue inflammation
  • Insulin resistance
  • Obesity
  • Pioglitazone
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. / Esterson, Yonah B.; Zhang, Kehao; Koppaka, Sudha; Kehlenbrink, Sylvia; Kishore, Preeti; Raghavan, Pooja; Maginley, Sylvan Roger; Carey, Michelle; Hawkins, Meredith A.

In: Journal of Investigative Medicine, Vol. 61, No. 8, 12.2013, p. 1152-1160.

Research output: Contribution to journalArticle

Esterson, Yonah B. ; Zhang, Kehao ; Koppaka, Sudha ; Kehlenbrink, Sylvia ; Kishore, Preeti ; Raghavan, Pooja ; Maginley, Sylvan Roger ; Carey, Michelle ; Hawkins, Meredith A. / Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. In: Journal of Investigative Medicine. 2013 ; Vol. 61, No. 8. pp. 1152-1160.
@article{4dc4d19007d7484c82d4c48ba5ce6f77,
title = "Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients",
abstract = "Objective: The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using indepth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. Materials and Methods: Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, doubleblind, crossover study. Each subject underwent a pair of {"}stepped{"} pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo. Results: Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat {"}browning{"} (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1). Conclusions: These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.",
keywords = "Adipose tissue inflammation, Insulin resistance, Obesity, Pioglitazone, Type 2 diabetes",
author = "Esterson, {Yonah B.} and Kehao Zhang and Sudha Koppaka and Sylvia Kehlenbrink and Preeti Kishore and Pooja Raghavan and Maginley, {Sylvan Roger} and Michelle Carey and Hawkins, {Meredith A.}",
year = "2013",
month = "12",
doi = "10.231/JIM.0000000000000017",
language = "English (US)",
volume = "61",
pages = "1152--1160",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients

AU - Esterson, Yonah B.

AU - Zhang, Kehao

AU - Koppaka, Sudha

AU - Kehlenbrink, Sylvia

AU - Kishore, Preeti

AU - Raghavan, Pooja

AU - Maginley, Sylvan Roger

AU - Carey, Michelle

AU - Hawkins, Meredith A.

PY - 2013/12

Y1 - 2013/12

N2 - Objective: The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using indepth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. Materials and Methods: Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, doubleblind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo. Results: Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1). Conclusions: These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.

AB - Objective: The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using indepth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. Materials and Methods: Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, doubleblind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo. Results: Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1). Conclusions: These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.

KW - Adipose tissue inflammation

KW - Insulin resistance

KW - Obesity

KW - Pioglitazone

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84896799696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896799696&partnerID=8YFLogxK

U2 - 10.231/JIM.0000000000000017

DO - 10.231/JIM.0000000000000017

M3 - Article

C2 - 24141239

AN - SCOPUS:84896799696

VL - 61

SP - 1152

EP - 1160

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 8

ER -